Literature DB >> 2479677

1F7, a novel cell surface molecule, involved in helper function of CD4 cells.

C Morimoto1, Y Torimoto, G Levinson, C E Rudd, M Schrieber, N H Dang, N L Letvin, S F Schlossman.   

Abstract

We have developed a monoclonal antibody, anti-1F7, that inhibits soluble Ag-driven T cell proliferation as well as PWM-driven IgG synthesis. Anti-1F7 antibody reacts with approximately 57% of unfractionated T cells, 62% of CD4+ cells, and 54% of CD8+ cells. Although the 1F7 Ag is widely distributed among lymphoid cells, this Ag on CD4+ cells is preferentially expressed on the CDw29(4B4+) helper population. Moreover, anti-1F7 antibody further subdivides the CD4+CDw29+ cell subset into CDw29+1F7+ and CDw29+1F7- populations. The CD4+CDw29+1F7+ population of cells maximally proliferates to recall Ag such as tetanus toxoid, whereas helper function for PWM-driven IgG synthesis by B cells belongs to both the CD4+CDw29+1F7+ and CD4+CDw29+1F7- population of cells. The most prominent structure defined by this antibody is a 110-kDa molecule that is different from the 135-kDa, 160-kDa, and 185-kDa glycoproteins identified by anti-CDw29 antibody and the 180-kDa glycoprotein identified by UCHL-1 antibody. It is, however, related to the molecule recognized by anti-Ta1, an activation Ag on T cells. Furthermore, although the Ta1 molecule is recognized by anti-1F7 mAb, the 1F7 family of structures also includes molecules distinct from Ta1.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2479677

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  56 in total

1.  CD26-mediated signaling for T cell activation occurs in lipid rafts through its association with CD45RO.

Authors:  T Ishii; K Ohnuma; A Murakami; N Takasawa; S Kobayashi; N H Dang; S F Schlossman; C Morimoto
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-02       Impact factor: 11.205

2.  CD26 T cells in the pathogenesis of asthma.

Authors:  K Ohnuma; T Yamochi; O Hosono; C Morimoto
Journal:  Clin Exp Immunol       Date:  2005-01       Impact factor: 4.330

3.  Induction of the 2B9 antigen/dipeptidyl peptidase IV/CD26 on human natural killer cells by IL-2, IL-12 or IL-15.

Authors:  T Yamabe; K Takakura; K Sugie; Y Kitaoka; S Takeda; Y Okubo; K Teshigawara; J Yodoi; T Hori
Journal:  Immunology       Date:  1997-05       Impact factor: 7.397

4.  The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes.

Authors:  C C Bleul; L Wu; J A Hoxie; T A Springer; C R Mackay
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-04       Impact factor: 11.205

5.  Inhibitors of dipeptidyl peptidase IV induce secretion of transforming growth factor-beta 1 in PWM-stimulated PBMC and T cells.

Authors:  D Reinhold; U Bank; F Bühling; U Lendeckel; J Faust; K Neubert; S Ansorge
Journal:  Immunology       Date:  1997-07       Impact factor: 7.397

6.  CD26 mediates dissociation of Tollip and IRAK-1 from caveolin-1 and induces upregulation of CD86 on antigen-presenting cells.

Authors:  Kei Ohnuma; Tadanori Yamochi; Masahiko Uchiyama; Kunika Nishibashi; Satoshi Iwata; Osamu Hosono; Hiroshi Kawasaki; Hirotoshi Tanaka; Nam H Dang; Chikao Morimoto
Journal:  Mol Cell Biol       Date:  2005-09       Impact factor: 4.272

7.  The costimulatory activity of the CD26 antigen requires dipeptidyl peptidase IV enzymatic activity.

Authors:  T Tanaka; J Kameoka; A Yaron; S F Schlossman; C Morimoto
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-15       Impact factor: 11.205

8.  CD26 induces T-cell proliferation by tyrosine protein phosphorylation.

Authors:  E Muñoz; M V Blazquez; J A Madueño; G Rubio; J Peña
Journal:  Immunology       Date:  1992-09       Impact factor: 7.397

9.  Involvement of dipeptidyl peptidase IV in an in vivo immune response.

Authors:  T Kubota; G R Flentke; W W Bachovchin; B D Stollar
Journal:  Clin Exp Immunol       Date:  1992-08       Impact factor: 4.330

10.  Effect of CD26/dipeptidyl peptidase IV on Jurkat sensitivity to G2/M arrest induced by topoisomerase II inhibitors.

Authors:  U Aytac; K Sato; T Yamochi; T Yamochi; K Ohnuma; G B Mills; C Morimoto; N H Dang
Journal:  Br J Cancer       Date:  2003-02-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.